New selective PAD4 inhibitors binding a calcium-deficient type of the PAD4 enzyme have validated the essential enzymatic part of human and mouse PAD4 in both of those histone citrullination and neutrophil extracellular lure formation for, to our understanding, The 1st time. The therapeutic potential of PAD4 inhibitors can now be https://geronimox211lxi4.wssblogs.com/profile